1. Clinical presentation & outcomes of stent thrombosis Spanish registry ESTROFA (n=23,500)
Overall
(n=301)
Acute/Subacute
(n=149)
Late
(n=152) p
Presentation
STEMI
83.7%
86%
81.5%
0.36
Shock
20.5%
21%
20.4%
0.98
TIMI 0/1
88%
92%
84.2%
0.056
Outcomes
In-hospital
Death
11.6%
13%
9.8%
Thrombosis
1.66%
2.7%
0.66%
Follow-up
n=216
n=128
n=133
Time, mo
11.810
1511
8.87.6
Death
16%
18.8%
13.1%
Thrombosis
4.6% 6%
3.3%
J Am Coll Cardiol 2008;51:986–90

2. DECREASE Study Design
The patients undergoing successful DES implantation
Operator decisions for adding cilostazol
Triple group (n=1443)
Dual group (n=1656)
Inverse-Probability-of-Treatment-Weighted (IPTW) for the Entire cohort
Propensity score matching (965 pairs)
Triple antiplatelet group (n=965)
Dual antiplatelet group (n=965)
Clinical follow-up at 12 months (Death, MI, or stent thrombosis)

3. Study endpoint 12-month clinical outcomes Primary endpoint Death
Myocardial infarction
Stent thrombosis (definite and probable by ARC)
Secondary endpoint
Death or Myocardial infarction
TIMI Major bleeding
TIMI minor bleeding

4. Inverse-probability-of-treatment weighted
Twelve-month risk of Events after DES Implantation of Triple versus Dual antiplatelet therapy according to analytic methods
Variables
Crude
Inverse-probability-of-treatment weighted
Propensity-matched
(965 pairs)
Hazard Ratio
(95% CI) P
Value
Hazard Ratio
(95% CI) P
Value
Hazard Ratio
(95% CI) P
Value
Cardiac events
Death
0.925 ( )
0.7907
0.762 ( )
0.4062
0.644( )
0.2584 MI
0.381 ( )
0.0617
0.233 ( )
0.0097
0.298 ( )
0.0665
Stent thrombosis
0.286 ( )
0.0524
0.136 ( )
0.0036
0.124 ( )
0.0496
Death/MI
0.761 ( )
0.2817
0.591 ( )
0.0665
0.556 ( )
0.0811
Bleeding
Major bleeding
0.850 ( )
0.5830
0.969 ( )
0.9372
0.683 ( )
0.2781
Minor bleeding
1.039 ( )
0.8125
1.062 ( )
0.7504
1.045 ( )
0.8267
Hazard ratios are for the triple group, as compared with the dual group.

5. Adjusted Landmark Analysis using IPTW in
patients without events at landmark months
Triple therapy beyond 1 month, Triple therapy (n=974) vs. Dual therapy (n=1646)
Outcome HR
95%CI
p-value
Death
1.192
0.591
2.403
0.6238
Myocardial infarction
0.346
0.088
1.365
0.1295
Stent thrombosis
0.108
0.013
0.918
0.0415
Death/ Myocardial infarction
0.931
0.493
1.758
0.8262
Triple therapy beyond 3 month, Triple therapy (n=394) vs. Dual therapy (n=1638)
Outcome HR
95%CI
p-value
Death
0.832
0.183
3.776
0.8116 MI
0.553
0.066
4.615
0.5841
Stent thrombosis NA NA NA NA
Death/ Myocardial infarction
0.754
0.210
2.704
0.6645
Triple therapy beyond 6 month, Triple therapy (n=253) vs. Dual therapy (n=1631)
Outcome HR
95%CI
p-value
Death
0.709
0.090
5.570
0.7441 MI NA
Stent thrombosis NA
Death/ Myocardial infarction
0.474
0.062
3.611
0.4711